Combination of checkpoint kinase i inhibitors and wee i kinase inhibitors
AssigneeArray BioPharma Inc.
InventorsKurtis D. Davies, Stefan Gross
Life of this patent
Estimating the term…
Abstract
A combination of a CHK1 inhibitor and a WEE1 inhibitor are provided.
Claims93
A use of a CHK1 inhibitor selected from the group consisting of the '926 CHK1 Inhibitors in combination with a WEE1 inhibitor.
A use of a CHK1 inhibitor selected from the group consisting of the '926 CHK1 Inhibitors in combination with a WEE1 inhibitor to treat cancer.
A use of a pharmaceutical composition comprising a CHK1 inhibitor selected from the group consisting of the '926 CHK1 Inhibitors in combination with a pharmaceutical composition comprising a WEE1 inhibitor to treat a hyperproliferative disease, such as cancer.
A use of a pharmaceutical composition comprising an effective amount of a CHK1 inhibitor selected from the group consisting of the '926 CHK1 Inhibitors in combination with a pharmaceutical composition comprising an effective amount of a WEE1 inhibitor to treat cancer.
A use of a CHK1 inhibitor selected from the group consisting of the '926 CHK1 Inhibitors for the manufacture of a medicament for the combined use with a WEE1 inhibitor in the treatment of a hyperproliferative disease, such as cancer.
A pharmaceutical composition comprising a CHK1 inhibitor selected from the group consisting of the '926 CHK1 Inhibitors and a WEE1 inhibitor.
A pharmaceutical composition comprising an effective amount of a CHK1 inhibitor selected from the group consisting of the '926 CHK1 Inhibitors and an effective amount of a WEE1 inhibitor.
A pharmaceutical composition for the treatment or prevention of cancer, comprising a CHK1 inhibitor selected from the group consisting of the '926 CHK1 Inhibitors and a WEE1 inhibitor.
A pharmaceutical composition for the treatment or prevention of cancer, comprising an effective amount of a CHK1 inhibitor selected from the group consisting of the '926 CHK1 Inhibitors and an effective amount of a WEE1 inhibitor.
A method for treating or preventing cancer by administering a CHK1 inhibitor selected from the group consisting of the '926 CHK1 Inhibitors in combination with a WEE1 inhibitor.
A method for treating or preventing cancer by administering an effective amount of a CHK1 inhibitor selected from the group consisting of the '926 CHK1 Inhibitors in combination with an effective amount of a WEE1 inhibitor.
A method for treating or preventing a hyperproliferative disease, such as cancer, by administering a CHK1 inhibitor selected from the group consisting of the '926 CHK1 Inhibitors in combination with a WEE1 inhibitor, wherein the CHK1 inhibitor is administered at or between the biologically effective dose and the maximum tolerated dose, and the WEE1 inhibitor is administered between the biologically effective dose and the maximum tolerated dose.
A method for treating or preventing a hyperproliferative disease, such as cancer, comprising administering to a mammal in need an effective amount of a CHK1 inhibitor selected from the group consisting of the '926 CHK1 Inhibitors in combination with an effective amount of a WEE1 inhibitor.
A kit comprising a CHK1 inhibitor selected from the group consisting of the '926 CHK1 Inhibitors and a WEE1 inhibitor.
A kit comprising:
- (a) a CHK1 inhibitor selected from the group consisting of the '926 CHK1 Inhibitors, and
- (b) a WEE1 inhibitor,
- for use in combination to treat or prevent a hyperproliferative disease, such as cancer.
A kit comprising:
- (a) a CHK1 inhibitor selected from the group consisting of the '926 CHK1 Inhibitors,
- (b) a WEE 1 inhibitor, and
- (c) a DNA damaging agent,
- for use in combination to treat or prevent a hyperproliferative disease, such as cancer.
A kit comprising:
- (a) a pharmaceutical composition comprising a CHK1 inhibitor selected from the group consisting of the '926 CHK1 Inhibitors, and
- (b) a pharmaceutical composition comprising a WEE1 inhibitor,
- for use in combination to treat or prevent a hyperproliferative disease, such as cancer.
A kit comprising:
- (a) a pharmaceutical composition comprising a CHK1 inhibitor selected from the group consisting of the '926 CHK1 Inhibitors,
- (b) a pharmaceutical composition comprising a WEE1 inhibitor, and
- (c) a pharmaceutical composition comprising a DNA damaging agent,
- for use in combination to treat or prevent a hyperproliferative disease, such as cancer.
A kit comprising:
- (a) a pharmaceutical composition comprising an effective amount of a CHK1 inhibitor selected from the group consisting of the '926 CHK1 Inhibitors, and
- (b) a pharmaceutical composition comprising an effective amount of a WEE1 inhibitor, for use in combination to treat or prevent a hyperproliferative disease, such as cancer.
A kit comprising:
- (a) a pharmaceutical composition comprising an effective amount of a CHK1 inhibitor selected from the group consisting of the '926 CHK1 Inhibitors,
- (b) a pharmaceutical composition comprising an effective amount of a WEE1 inhibitor, and
- (c) a pharmaceutical composition comprising an effective amount of a DNA damaging agent,
- for use in combination to treat or prevent a hyperproliferative disease, such as cancer.
A use of a CHK1 inhibitor in combination with a WEE1 inhibitor.
A use of a CHK1 inhibitor in combination with a WEE1 inhibitor to treat cancer.
A use of a pharmaceutical composition comprising a CHK1 inhibitor in combination with a pharmaceutical composition comprising a WEE1 inhibitor to treat a hyperproliferative disease, such as cancer.
A use of a pharmaceutical composition comprising an effective amount of a CHK1 inhibitor in combination with a pharmaceutical composition comprising an effective amount of a WEE1 inhibitor to treat cancer.
A use of a CHK1 inhibitor for the manufacture of a medicament for the combined use with a WEE1 inhibitor in the treatment of a hyperproliferative disease, such as cancer.
A pharmaceutical composition comprising a CHK1 inhibitor and a WEE1 inhibitor.
A pharmaceutical composition comprising an effective amount of a CHK1 inhibitor and an effective amount of a WEE 1 inhibitor.
A pharmaceutical composition for the treatment or prevention of cancer, comprising a CHK1 inhibitor and a WEE1 inhibitor.
A pharmaceutical composition for the treatment or prevention of cancer, comprising an effective amount of a CHK1 inhibitor and an effective amount of a WEE1 inhibitor.
A method for treating or preventing cancer by administering a CHK1 inhibitor in combination with a WEE1 inhibitor.
A method for treating or preventing cancer by administering an effective amount of a CHK1 inhibitor in combination with an effective amount of a WEE1 inhibitor.
A method for treating or preventing a hyperproliferative disease, such as cancer, by administering a CHK1 inhibitor in combination with a WEE1 inhibitor, wherein the CHK1 inhibitor is administered at or between the biologically effective dose and the maximum tolerated dose, and the WEE1 inhibitor is administered between the biologically effective dose and the maximum tolerated dose.
A method for treating or preventing a hyperproliferative disease, such as cancer, comprising administering to a mammal in need an effective amount of a CHK1 inhibitor in combination with an effective amount of a WEE1 inhibitor.
A kit comprising a CHK1 inhibitor and a WEE1 inhibitor.
A kit comprising:
- (a) a CHK1 inhibitor, and
- (b) a WEE1 inhibitor,
- for use in combination to treat or prevent a hyperproliferative disease, such as cancer.
A kit comprising:
- (a) a CHK1 inhibitor,
- (b) a WEE1 inhibitor, and
- (c) a DNA damaging agent,
- for use in combination to treat or prevent a hyperproliferative disease, such as cancer.
A kit comprising:
- (a) a pharmaceutical composition comprising a CHK1 inhibitor, and
- (b) a pharmaceutical composition comprising a WEE1 inhibitor,
- for use in combination to treat or prevent a hyperproliferative disease, such as cancer.
A kit comprising:
- (a) a pharmaceutical composition comprising a CHK1 inhibitor,
- (b) a pharmaceutical composition comprising a WEE1 inhibitor, and
- (c) a pharmaceutical composition comprising a DNA damaging agent,
- for use in combination to treat or prevent a hyperproliferative disease, such as cancer.
A kit comprising:
- (a) a pharmaceutical composition comprising an effective amount of a CHK1 inhibitor, and
- (b) a pharmaceutical composition comprising an effective amount of a WEE1 inhibitor,
- for use in combination to treat or prevent a hyperproliferative disease, such as cancer.
A kit comprising:
- (a) a pharmaceutical composition comprising an effective amount of a CHK1 inhibitor,
- (b) a pharmaceutical composition comprising an effective amount of a WEE1 inhibitor, and
- (c) a pharmaceutical composition comprising an effective amount of a DNA damaging agent,
- for use in combination to treat or prevent a hyperproliferative disease, such as cancer.
Dependencies are inferred from the claim text.